Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease

Juan Bautista Blaquier, Gonzalo Recondo

Article Type



In this article, the authors focus on the management of patients with MET exon 14 skipping alterations by addressing the biology of the MET receptor and exon 14 skipping mutations, current treatment strategies, and sequential treatment options based on resistance mechanisms to MET inhibitors in patients with non-small-cell lung cancer.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.